Endocrinol Metab.  2017 Mar;32(1):124-128. 10.3803/EnM.2017.32.1.124.

Serum Preadipocyte Factor 1 Levels Are Not Associated with Bone Mineral Density among Healthy Postmenopausal Korean Women

• Choi HS
• Kim SW
• Cho EH

• KMID: 2413296
• DOI: http://doi.org/10.3803/EnM.2017.32.1.124

Abstract

BACKGROUND
Multipotent mesenchymal stem cells can differentiate into adipocytes or osteoblasts through closely regulated lineage-control processes. However, adipocyte precursor cells release preadipocyte factor 1 (Pref-1), which inhibits the differentiation of mesenchymal stem cells into mature adipocytes and osteoblasts. Previous studies have also reported an inverse association between Pref-1 levels and bone mineral density (BMD) among patients with anorexia nervosa.
METHODS
In this retrospective study, we examined the correlations between Pref-1 levels and BMD among 124 healthy postmenopausal women (>50 years old). The patients had provided information regarding their clinical characteristics, and underwent blood testing and serum Pref-1 testing.
RESULTS
The subjects' mean age was 59.9±7.1 years and the median time since menopause onset was 9.1 years. A history of osteoporotic fracture was identified in 23 subjects (19%). Serum Pref-1 levels were not significantly correlated with BMD values at the lumbar spine (R²=0.038, P=0.109), femur neck (R²=0.017, P=0.869), and total hip (R²=0.041, P=0.09), and multivariate analyses with adjustment for age and body mass index also did not detect any significant correlations. Subgroup analyses according to a history of fracture also did not detect significant associations between Pref-1 levels and BMD values.
CONCLUSION
In our study population, it does not appear that serum Pref-1 levels are significantly associated with BMD values and osteoporosis.

Keyword

Preadipocyte factor 1; Postmenopausal women; Bone density; Osteoporosis

MeSH Terms

Adipocytes
Anorexia Nervosa
Body Mass Index
Bone Density*
Female
Femur Neck
Hematologic Tests
Hip
Humans
Menopause
Mesenchymal Stromal Cells
Multivariate Analysis
Osteoblasts
Osteoporosis
Osteoporotic Fractures
Retrospective Studies
Spine

Reference

1. Park EJ, Joo IW, Jang MJ, Kim YT, Oh K, Oh HJ. Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008-2011. Yonsei Med J. 2014; 55:1049–1057.

2. Abdallah BM, Kassem M. New factors controlling the balance between osteoblastogenesis and adipogenesis. Bone. 2012; 50:540–545.

3. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci. 1992; 102(Pt 2):341–351.

4. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. The International Society for Cellular Therapy position statement. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006; 8:315–317.

5. Sul HS. Minireview: Pref-1: role in adipogenesis and mesenchymal cell fate. Mol Endocrinol. 2009; 23:1717–1725.

6. Abdallah BM, Ditzel N, Mahmood A, Isa A, Traustadottir GA, Schilling AF, et al. DLK1 is a novel regulator of bone mass that mediates estrogen deficiency-induced bone loss in mice. J Bone Miner Res. 2011; 26:1457–1471.

7. Berends MJ, Hordijk R, Scheffer H, Oosterwijk JC, Halley DJ, Sorgedrager N. Two cases of maternal uniparental disomy 14 with a phenotype overlapping with the Prader-Willi phenotype. Am J Med Genet. 1999; 84:76–79.

8. Kotzot D. Abnormal phenotypes in uniparental disomy (UPD): fundamental aspects and a critical review with bibliography of UPD other than 15. Am J Med Genet. 1999; 82:265–274.

9. Fazeli PK, Bredella MA, Misra M, Meenaghan E, Rosen CJ, Clemmons DR, et al. Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab. 2010; 95:407–413.

10. Aronis KN, Kilim H, Chamberland JP, Breggia A, Rosen C, Mantzoros CS. Preadipocyte factor-1 levels are higher in women with hypothalamic amenorrhea and are associated with bone mineral content and bone mineral density through a mechanism independent of leptin. J Clin Endocrinol Metab. 2011; 96:E1634–E1639.

11. Kim SW, Lee HA, Cho EH. Low handgrip strength is associated with low bone mineral density and fragility fractures in postmenopausal healthy Korean women. J Korean Med Sci. 2012; 27:744–747.

12. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem. 2006; 98:251–266.

13. Fazeli PK, Ackerman KE, Pierce L, Guereca G, Bouxsein M, Misra M. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes. Osteoporos Int. 2013; 24:2433–2440.

14. Faje AT, Fazeli PK, Katzman D, Miller KK, Breggia A, Rosen CJ, et al. Inhibition of Pref-1 (preadipocyte factor 1) by oestradiol in adolescent girls with anorexia nervosa is associated with improvement in lumbar bone mineral density. Clin Endocrinol (Oxf). 2013; 79:326–332.

15. Fazeli PK, Bredella MA, Freedman L, Thomas BJ, Breggia A, Meenaghan E, et al. Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res. 2012; 27:1864–1871.

16. Abdallah BM, Bay-Jensen AC, Srinivasan B, Tabassi NC, Garnero P, Delaisse JM, et al. Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. J Bone Miner Res. 2011; 26:2548–2551.

17. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995; 87:1297–1302.

18. Cauley JA. Estrogen and bone health in men and women. Steroids. 2015; 99(Pt A):11–15.

19. Williams GR. Thyroid hormone actions in cartilage and bone. Eur Thyroid J. 2013; 2:3–13.

20. Rizzoli R. Nutritional aspects of bone health. Best Pract Res Clin Endocrinol Metab. 2014; 28:795–808.

21. Christianson MS, Shen W. Osteoporosis prevention and management: nonpharmacologic and lifestyle options. Clin Obstet Gynecol. 2013; 56:703–710.